Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB

被引:99
作者
Baumli, Sonja [1 ]
Endicott, Jane A. [1 ]
Johnson, Louise N. [1 ]
机构
[1] Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England
来源
CHEMISTRY & BIOLOGY | 2010年 / 17卷 / 09期
基金
英国医学研究理事会;
关键词
TRANSCRIPTION; FLAVOPIRIDOL;
D O I
10.1016/j.chembiol.2010.07.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cdk9, the kinase of the positive transcription elongation factor b, is required for processive transcription elongation by RNA polymerase II. Cdk9 inhibition contributes to the anticancer activity of many Cdk inhibitors under clinical investigation and hence there is interest in selective Cdk9 inhibitors. DRB (5,6-dichlorobenzimidazone-1-beta-D-ribofuranoside) is a commonly used reagent for Cdk9 inhibition in cell biology studies. The crystal structures of Cdk9 and Cdk2 in complex with DRB reported here describe the molecular basis for the DRB selectivity toward Cdk9. The DRB chlorine atoms form halogen bonds that are specific for the Cdk9 kinase hinge region. Kinetic and thermodynamic experiments validate the structural findings and implicate the C-terminal residues of Cdk9 in contributing to the affinity for DRB. These results open the possibility to exploit halogen atoms in inhibitor design to specifically target Cdk9.
引用
收藏
页码:931 / 936
页数:6
相关论文
共 20 条
[1]  
Afonine P.V., 2005, CCP4 Newsl, V42, P8
[2]   Halogen bonds in biological molecules [J].
Auffinger, P ;
Hays, FA ;
Westhof, E ;
Ho, PS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (48) :16789-16794
[3]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[4]   Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole [J].
Battistutta, R ;
Mazzorana, M ;
Sarno, S ;
Kazimierczuk, Z ;
Zanotti, G ;
Pinna, LA .
CHEMISTRY & BIOLOGY, 2005, 12 (11) :1211-1219
[5]   The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation [J].
Baumli, Sonja ;
Lolli, Graziano ;
Lowe, Edward D. ;
Troiani, Sonia ;
Rusconi, Luisa ;
Bullock, Alex N. ;
Debreczeni, Judit E. ;
Knapp, Stefan ;
Johnson, Louise N. .
EMBO JOURNAL, 2008, 27 (13) :1907-1918
[6]   The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases [J].
Brown, NR ;
Noble, MEM ;
Endicott, JA ;
Johnson, LN .
NATURE CELL BIOLOGY, 1999, 1 (07) :438-443
[7]   Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia [J].
Byrd, John C. ;
Lin, Thomas S. ;
Dalton, James T. ;
Wu, Di ;
Phelps, Mitch A. ;
Fischer, Beth ;
Moran, Mollie ;
Blum, Kristie A. ;
Rovin, Brad ;
Brooker-McEldowney, Michelle ;
Broering, Sarah ;
Schaaf, Larry J. ;
Johnson, Amy J. ;
Lucas, David M. ;
Heerema, Nyla A. ;
Lozanski, Gerard ;
Young, Donn C. ;
Suarez, Jose-Ramon ;
Colevas, A. Dimitrios ;
Grever, Michael R. .
BLOOD, 2007, 109 (02) :399-404
[8]   Transcription regulation through promoter-proximal pausing of RNA polymerase II [J].
Core, Leighton J. ;
Lis, John T. .
SCIENCE, 2008, 319 (5871) :1791-1792
[9]   Alternative binding modes of an inhibitor to two different kinases [J].
De Moliner, E ;
Brown, NR ;
Johnson, LN .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2003, 270 (15) :3174-3181
[10]  
Lam LT, 2001, GENOME BIOL, V2